Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Impact
If enacted, AB A3030 will alter the current framework of the prescription monitoring program. It will introduce a formal process whereby patients can request their prescription records to indicate their preferences against certain medications. The implementation of these changes in law will necessitate the Division of Consumer Affairs to establish clear protocols for the inclusion and eventual removal of these patient preferences from their prescription records, thereby enhancing patient autonomy in medical decisions.
Summary
Assembly Bill A3030, sponsored by Assemblyman Clinton Calabrese, seeks to amend existing regulations surrounding the prescription monitoring program in New Jersey. The primary objective of this bill is to allow patients to explicitly state that they do not wish to be prescribed opioid drugs or other controlled substances with a high potential for abuse and addiction. This provision aims to empower patients in their recovery journeys, especially those struggling with substance dependence, by preventing doctors from prescribing medications that could jeopardize their sobriety.
Contention
Despite its intention to bolster patient safety and autonomy, Bill A3030 may encounter opposition regarding its implementation. Critics may argue that allowing patients to refuse certain prescriptions could complicate treatment for legitimate pain management and may lead to inadequate care for patients who might benefit from those medications. Furthermore, there are concerns over ensuring that healthcare providers are accurately informed of a patient's prescriptions and preferences, especially in emergencies where patients may be incapacitated and unable to communicate.
Same As
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Carry Over
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Carry Over
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.
Requires hospital and emergency room physicians to consult the prescription monitoring program registry and to notify a patient's prescriber that such patient is being treated for a controlled substance overdose.
Expands definition of personal data to include use of reproductive health care services and prohibits collection of reproductive health care prescription drugs from Prescription Monitoring Program.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.